Article

Shaji Kumar on Later Lines of Treatment for Myeloma

Author(s):

There are several agents available for patients who experience recurrence, Kumar says, though nearly all of them have the potential to move to an earlier setting.

Shaji Kumar, professor of medicine, Division of Hematology, Mayo Clinic, provides an overview of later lines of therapy for patients with multiple myeloma.

There are several agents available for patients who experience recurrence, Kumar says, though nearly all of them have the potential to move to an earlier setting.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Image of doctor.
Image of man with black hair.
Picture of Dr. Pouneh Razavi
Richard Winneker gathers input from patients and researchers to shape MPN research, aiming to fund strategic projects for this population.
Dr. Curtiland Deville Jr. discusses the importance of crafting an individualized treatment plan for patients with prostate cancer.
Image of Crispino
Image of Dr. Reznick
Picture of Joy Anderson
Some patients with relapsed/refractory diffuse large B-cell lymphoma whose disease progressed after CAR-T cell therapy, responded to odronextamab.
Anne M. Reb is a nurse practitioner with City of Hope.
Related Content